Table 1 Clinical and demographic characteristics of the RA patients
| Â | Â | Â | Â | Treatment trial | |
|---|---|---|---|---|---|
| Â | Healthy controls | Long-standing RA | RA patients for synovium collection | MTX only | Infliximab and MTX |
Number of subjects | 40 | 33 | 10 | 8 | 15 |
Age (years) | 44 ± 9 | 57 ± 12 | 62 ± 10 | 52 ± 16 | 45 ± 11 |
Female/male ratio | 26:14 | 28:5 | 9:1 | 7:1 | 13:2 |
Disease duration (years) | -- | 13 ± 12 | 13.5 ± 11.0 | 5.7 ± 1.5 | 3.0 ± 0.5 |
% RF positive patients | -- | 79% | 90% | 50% | 73% |
ESR (mm/hour) | -- | 36 ± 27 | -- | 36.9 ± 14.3 | 60.2 ± 30.3 |
CRP (mg/dl) | -- | <0.4 ± 9.75 | 2.8 ± 2.3 | 0.8 ± 1.1 | 1.8 ± 1.9 |
% Patients on MTX (dose) | -- | 85% (15 mg/wk) | 60% (4 mg/wk) | 100% (14 mg/wk) | 100% (14 mg/wk) |
% Patients on GC (dose) | -- | 49% (5 mg/day) | 80% (5 mg/day) | 50% (6 mg/day) | 64% (6 mg/day) |
% Patients on other DMARD | -- | 82% | 50% | -- | -- |